Knowledge Gaps Identified in Treating Recurrent Ovarian Cancer With PARP Inhibitors

As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such as patient health status, predictive/prognostic markers, disease-free interval, number of lines and agents used previously, toxicities remaining from previous lines of therapy, and the extent of disease relapse. The new research constantly being conducted creates anoth...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Regarding PARP Inhibitor Therapies

Poly(ADP)-ribose polymerase (PARP) inhibition is a new form of targeted therapy that has exhibited effectiveness in treating several solid tumor types. Olaparib (Lynparza®, AstraZeneca), rucaparib (Rubraca®, Clovis Oncology), and niraparib (Zejula®, Tesaro) have all been approved for the treatment of advanced ovarian cancer. Olaparib has also been approved to treat BRCA-mutated breast cancer and is currently being investigated in the treatment of prostate cancer. Another PARP inhibitor, talazopa...
Continue reading

DNA Damage Repair Inhibitors Fight Small Cell Lung Cancer

Patients with small cell lung cancer (SCLC) often do not respond to immune checkpoint blockade therapy alone. However, researchers at the University of Texas MD Anderson Cancer Center now report that a combination of immune checkpoint blockade therapy and targeted therapies blocking DNA damage repair significantly shrinks tumors in mouse models of SCLC. "While the use of immunotherapy has revolutionized the way we treat lung cancer, we find that small cell lung cancers can escape the immune syst...
Continue reading

Current Challenges and Promising Advances in Recurrent Ovarian Cancer With Ursula Matulonis, MD

Ovarian cancer accounts for 5% of cancer deaths among women in the United States and causes more deaths than any other cancer of the female reproductive system. An estimated 22,240 new cases are diagnosed annually, and 14,070 people die of the disease. Relative survival varies by age; women younger than 65 are much more likely to survive 5 years (77%) following diagnosis than women 65 and older (20%). Overall, the 5-year relative survival rate for ovarian cancer patients is 47%. If diagnosed at ...
Continue reading

Talazoparib Approved: Advanced HER2-Negative Breast Cancer With gBRCA Mutations

​Talazoparib (Talzenna®, Pfizer Inc.), an orally available poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the United States Food and Drug Administration (FDA) for the treatment of patients with HER2-negative locally advanced or metastatic breast cancer with known or suspected deleterious germline BRCA (gBRCA) mutations. Eligibility for talazoparib therapy must be determined using the BRACAnalysis CDx® test (Myriad Genetic Laboratories Inc.), which the FDA has also approved a...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.